Print Page  |  Close Window

2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
April 15, 2019
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
April 03, 2019
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c)(4)
April 02, 2019
Voyager Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
March 28, 2019
Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
February 26, 2019
Voyager Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
February 22, 2019
Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies
February 19, 2019
Voyager Therapeutics to Present at Upcoming Investor Conferences
February 18, 2019
Voyager Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
January 29, 2019
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia
January 22, 2019
Voyager Therapeutics Appoints Robert Hesslein as General Counsel
January 15, 2019
Voyager Therapeutics to Appoint Omar Khwaja, M.D., Ph.D., as Chief Medical Officer
January 07, 2019
Voyager Therapeutics Provides Updates for VY-AADC Clinical Program for Parkinson’s Disease